## **Post Authorisation Assessments**

## CEVAC IBird Lyophilisate for Oculonasal Suspension/Use in Drinking Water for Chickens

Vm 15052/3011

| Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV). Introduction of a summary of the PSMF.   |
|--|
| Update of the QRD/SPC templates in accordance with Regulation (EU) 2019/6.   |
| Change of MAH address from: Unit 3 Anglo Office Park, White Lion Road, Amersham, Buckinghamshire, HP7 9FB to Explorer House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0HH, United Kingdom.                           |
| Change in the number of units in a pack outside the range of the currently approved pack sizes of the finished product.  Qualitative and quantitative changes to the excipients.   |
| Renewal – UK as CMS  |
| Change / Replacement of a test procedure for the finished product.   |
| Change in the QPPV of an existing pharmacovigilance system as described in the DDPS.  Change of the back-up procedure of the QPPV of an existing pharmacovigilance system as described in the DDPS.  |
| Addition of a new therapeutic indication / modification of an approved indication.  Addition of a new therapeutic indication / modification of an approved indication.  Addition of a new therapeutic indication / modification of an approved indication. |
| Submission of a revised DDPS.  |
| Mock-ups amended to include multi-lingual text.  |
| Change to the MAH address in Slovakia and Czech Republic only.   |
| Changes to an existing pharmacovigilance system as described in the DDPS.  |
|  |